Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MARS--does it stand the test of time?

Kevin D Mullen1, Srinivasan Dasarathy

  • 1GI Division, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio 44109, USA. kdm@po.cwru.edu

Metabolic Brain Disease
|November 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sparse CCA-Based Mediation Analysis with High-Dimensional Exposures and Mediators.

Bioinformatics (Oxford, England)·2026
Same author

Urine Proteomic Profiling at Admission Reveals Complement Biomarkers Linked to Alcohol-Associated Liver Disease.

Alcohol, clinical & experimental research·2026
Same author

The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease.

Nature communications·2026
Same author

Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial.

Hepatology (Baltimore, Md.)·2026
Same author

Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients with Severe Alcohol-associated Hepatitis.

Clinical and translational gastroenterology·2026
Same author

SIRPα Cleavage Is Associated with Inflammatory Response, Corticosteroid Nonresponse, and Worse Prognosis in Clinical and Preclinical Models of Alcohol-Associated Hepatitis.

The American journal of pathology·2026

Molecular absorbent recycling systems (MARS), or extracorporeal albumin dialysis (ECAD), show promise in treating liver failure. This liver support technique has demonstrated improved survival in acute on chronic liver failure patients.

Area of Science:

  • Hepatology
  • Biomedical Engineering
  • Artificial Organ Development

Background:

  • Liver failure management remains a significant clinical challenge.
  • Artificial liver support systems have historically yielded limited success in controlled trials.
  • Recent advancements include the Molecular Absorbent Recycling System (MARS) and Extracorporeal Albumin Dialysis (ECAD).

Purpose of the Study:

  • To evaluate the efficacy and potential of the MARS/ECAD technique in liver failure management.
  • To assess the current evidence supporting the use of ECAD in acute liver failure (ALF) and acute on chronic liver failure (AOCLF).

Main Methods:

  • Review of existing clinical data and controlled trials on MARS/ECAD.
  • Comparison of ECAD outcomes against standard supportive therapy in AOCLF patients.

Related Experiment Videos

  • Assessment of patient survival rates in randomized control groups.

    • Main Results:

    • ECAD has shown potential to overcome previous limitations of artificial liver support.
    • Data for ECAD in ALF is limited, but promising in AOCLF.
    • ECAD demonstrated improved survival in AOCLF patients compared to standard care.

    Conclusions:

    • The ECAD technique represents a potential breakthrough in liver support, showing sustained effectiveness.
    • Further well-designed multicenter trials are necessary to confirm ECAD's efficacy.
    • ECAD may play a crucial role in managing critically ill liver failure patients awaiting transplantation.